Renin-angiotensin system blockers and residual kidney function loss in patients initiating peritoneal dialysis: an observational cohort study

Table 2 Number of patients, events, follow-up time, incidence rates, and hazard ratios for anuria in an IPTW cohort

Cohort	Analysis	Exposure group	N	Number of events	Follow-up time (years)		Incidence rate (per 100 person-years)	Hazard ratio (95% CI)
					Mean ± SD	Median
Full cohort	ITT	ACEI/ARB	389	121	1.05 ± 0.89	0.81	29.6	0.86 (0.73, 1.02)
Full cohort	ITT	Non-user	497	159	0.87 ± 0.82	0.62	36.9
Full cohort	AT	ACEI/ARB	389	53	0.35 ± 0.37	0.24		0.66 (0.51, 0.84)
Full cohort	AT	Non-user	497	91	0.30 ± 0.33	0.19
Baseline rGFR ≤20 ml/min	ITT	ACEI/ARB	379	118	1.05 ± 0.89	0.80		0.87 (0.74, 1.03)
Baseline rGFR ≤20 ml/min	ITT	Non-user	485	156	0.88 ± 0.82	0.62
≥1 year on PD cohort	ITT	ACEI/ARB	203	59	0.93 ± 0.80^a	0.71^a		0.98 (0.76, 1.27)
≥1 year on PD cohort	ITT	Non-user	209	58	0.85 ± 0.78^a	0.63^a

ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin-II receptor blocker, AT as treated, CI confidence interval, IPTW inverse probability of treatment weighted, ITT intention to treat, rGFR residual glomerular filtration rate, SD standard deviation
^aNote that follow-up for the ≥1 year on PD cohort began on day 365 of dialysis whereas in the other analyses follow-up began on day 90 of dialysis. Thus, patients in the ≥1 year on PD cohort were followed on average until day 690 of dialysis whereas patients in the unadjusted ITT analysis of the full cohort were followed on average until day 436 of dialysis

ISSN: 1471-2369